Vest Prevention of Early Sudden Death Trial (VEST)
|
|
|
- Dennis Bond
- 6 years ago
- Views:
Transcription
1 ACC Late Breaking Clinical Trials 2018 Vest Prevention of Early Sudden Death Trial (VEST) Jeffrey Olgin, MD, FACC Division of Cardiology, UCSF On behalf of the VEST Investigators
2 Disclosures ClinicalTrials.gov registration: NCT Funding NHLBI (U01HL & U01HL089145) funded Coordinating Centers until 2012 funded study throughout and Coordinating Centers after 2012
3 Background: SCD is high after MI Olmsted County VALIANT Trial Cumulative Incidence Death Sudden cardiac death Rate of Sudden Cardiac Death or Cardiac Arrest (%/mo) Time to Event (year) Months after Myocardial Infarction (mo) Adabag, et al. JAMA 2008 VALIANT Solomon, et al. NEJM 2005
4 Background: No benefit from early ICD Total Mortality DINAMIT ICD group Control group Total Mortality IRIS ICD group Control group SCD Mortality Control group ICD group DINAMIT: Hohnloser, et al. NEJM 2004 IRIS: Steinbeck, et al. NEJM 2009 Cumulative Risk of Death from Arrhythmia Cumulative Risk of Death from Any Cause Cumulative Risk of Sudden Cardiac Death Cumulative Risk of Death from Any Cause SCD Mortality Control group ICD group
5 Background: No benefit from early ICD Total Mortality DINAMIT ICD group Control group Total Mortality IRIS ICD group Control group SCD Mortality Control group ICD group DINAMIT: Hohnloser, et al. NEJM 2004 IRIS: Steinbeck, et al. NEJM 2009 Cumulative Risk of Death from Arrhythmia Cumulative Risk of Death from Any Cause Cumulative Risk of Sudden Cardiac Death Cumulative Risk of Death from Any Cause SCD Mortality Control group ICD group
6 Background: No benefit from early ICD Cumulative Risk of Death from Any Cause Total Mortality DINAMIT ICD group Cumulative Risk of Death from Any Cause ICD group 1 Outcome: Long-term Control group (>30 month) mortality Control group N = 674 Total Mortality IRIS N = 898 Cumulative Risk of Death from Arrhythmia SCD Mortality Control group ICD group Cumulative Risk of Sudden Cardiac Death SCD Mortality Control group ICD group DINAMIT: Hohnloser, et al. NEJM 2004 IRIS: Steinbeck, et al. NEJM 2009
7 Background: Guideline recommendations Al-Khatib SM, et al VA/SCD Guidelines Primary Prevention of SCD in Patients with Ischemic Heart Disease Recommendations for Primary Prevention of SCD in Patients With Ischemic Heart Disease COR I LOE A Recommendations 1. InpatientswithLVEFof35%orlessthatisduetoischemicheartdiseasewho are at least 40 days post-mi and at least 90 days post revascularization, and with NYHA class II or III HF despite GDMT, an ICD is recommended if meaningful survival of greater than 1 year is expected(1,2) ACC/AHA/HRS Guideline for Management of Patients With Ventricular Arrhythmias. JACC 2017
8 Background: VEST rationale ICD not indicated in immediate post-mi period Some early mortality not due to arrhythmias immediately post-mi, thus not preventable by ICD LVEF may recover over 3 months post-mi Can a wearable cardioverter defibrillator (WCD) reduce SD mortality in the immediate post-mi period (<90 days) in patients with reduced LVEF, as a bridge to evaluation for ICD?
9 Methods: Study design Multi-center, randomized, open-label trial Participants enrolled within 7 days of hospital d/c with acute MI and EF 35% Randomized 2:1 to receive: Wearable cardioverter defibrillator (WCD) + guidelinedirected therapy or Guideline-directed medical therapy alone MD s & sites blinded to detected arrhythmias Crossovers & ICDs prohibited (except for secondary prevention during follow-up)
10 Methods: Inclusion & exclusion Inclusion Criteria 7 days of hospital discharge for acute MI EF 35% assessed: 8 hrs after MI 8 hrs after PCI 48 hrs after CABG Exclusion Criteria Existing ICD Significant valve disease Unipolar pacing system Chronic hemodialysis Chest too small/large for WCD Discharge to SNF for >7 days Pregnancy
11 Methods: Screening & enrollment Screening & enrollment between enrolling sites 76 US sites 6 German sites 24 Polish sites 2 Hungarian sites Alaska Germany United States Poland Hungary
12 Methods: Intervention-WCD Washable- Interchangeable Garment Self-Gelling Defibrillation Electrodes Dry ECG Electrodes Rechargeable Monitor & Battery Pack Response Buttons Monitors Wear-time Noise Device warning Asystole VT/VF Treatment VT/VF Investigators blinded to data
13 Methods: Outcomes Follow-up at 1 month & 3 months Search NDI at end of study Primary Outcome: SCD & death due to ventricular arrhythmias Secondary outcomes Total mortality & Non-sudden death Cause-specific death Non-fatal outcomes CV Hospitalizations WCD compliance Adverse events
14 Methods: Analysis plan Primary Analysis: Intention-to-treat Participants with indeterminate causes of death or unknown vital status are treated as not having primary outcome Secondary Analyses Weighted sensitivity analyses excluding unknown vital status and indeterminate causes of death from denominator
15 Results: CONSORT diagram Died Prior to Consent (n=797) Refused (n=546) WCD + Guideline Rx (n=1,524) Received WCD (n=1,481) Never wore WCD (n=43) ICD implant during FU (n=67) Analyzed (n=1524) Vital status unknown (n=10) Assessed for Eligibility (n=13,774) Randomized (n=2,302) 2:1 Excluded (n=10,129) Existing ICD (n=2,158) Chronic Renal Failure (n=1,148) Discharge to SNF (n=740) Unipolar pacing system (n=160) Chest too large/small (n=76) Significant valve disease (n=102) Pregnancy (n=8) Inability to consent (n=1,327) Unsuitable/Other (n=4,364) Guideline Rx (n=778) Never given WCD (n=758) Given WCD-protocol viol (n=20) ICD implant during FU (n=44) Mean Follow-up = 84.3 ± 15.6 days Analyzed (n=778) Vital status unknown (n=12)
16 Results: Participant characteristics Characteristic WCD Group (N=1524) Control Group (N=778) Age, mean ± SD 60.9 ± ± 12.3 Men, n (%) 1107 (72.8%) 577 (74.7%) Body mass index, Mean ± SD 28.4 ± ± 6.6 Smoker, n(%) 561 (36.9%) 273 (35.5%) Race n (%) White 1278 (84.1%) 636 (82.6%) Black 143 (9.4%) 75 (9.7%) Asian 23 (1.5%) 14 (1.8%) Native American/Alaskan 25 (1.7%) 12 (1.6%) Pacific Islander/Hawaiian 1 (0.1%) 0 (0%) Mixed 20 (1.3%) 14 (1.8%) Hispanic, n (%) 85 (5.6%) 34 (4.4%)
17 Results: Prior history Characteristic WCD Group (N=1524) Control Group (N=778) Diabetes Mellitus, n (%) 496 (32.6%) 246 (31.7%) Hypertension, n(%) 993 (65.3%) 501 (64.6%) Prior MI, n (%) 380 (25.1%) 193 (24.9%) Prior CABG, n (%) 133 (8.8%) 70 (9.0%) Prior PCI, n (%) 374 (24.6%) 202 (26.0%) Prior CHF, n (%) 246 (16.2%) 146 (18.9%) NYHA Classification, n (%) I 691 (45.5%) 326 (42.1%) II 528 (34.8%) 286 (36.9%) III 211 (13.9%) 116 (15.0%) IV 46 (3.0%) 18 (2.3%)
18 Results: Characteristics of index MI Characteristic WCD Group (N=1524) Control Group (N=778) LVEF 28.2 ± 6.1% 28.2 ± 5.9% PCI during MI hospitalization 1272 (84.2%) 650 (84.1%) Thrombolytics during MI hospitalization 118 (7.8%) 71 (9.2%) CABG during index hospitalization 14 (0.9%) 12 (1.5%) Cardiac Arrest/VF 169 (11.2%) 70 (9.1%) Pulmonary Edema requiring Intubation 162 (10. 7%) 88 (11.4%) Intra-aortic Balloon Pump 173 (11.5%) 93 (12.0%) Cardiogenic Shock 136 (9.0%) 79 (10.2%)
19 Results: Medical treatment Characteristic WCD Group (N=1524) Control Group (N=778) ASA 1328 (87.1%) 677 (87.0%) Other antiplatelet 1378 (90.4%) 679 (87.3%) Statin 1384 (90.8%) 695 (89.3%) Beta blocker (including carvedilol) 1407 (92.3%) 716 (92.0%) ACEI/ARB 1330 (87.3%) 665 (85.5%) Eplerenone/spironolactone 661 (43.4%) 342 (44.0%) Other diuretic 736 (48.3%) 384 (49.4%) Amiodarone 106 (7.0%) 55 (7.1%)
20 Results: Crossover treatment Characteristic WCD Group (N=1524) Control Group (N=778) WCD received, n (%) 1455 (95.5%) 20 (2.6%)* Average hours/day WCD worn 14.1 ± ± 3.9* ICD during follow up (<90 days), n (%) 67 (4.4%) 44 (5.7%) ICD Implant timing (days since randomization), median (IQR) 62 (24-81) 58 (25-77) *P <0.001
21 Results: WCD wear-time Percent (%) Mean Hrs worn Percent using WCD, by day Hours worn/day (incl non-users) Days since randomization Mean Hrs worn when used Hours worn on days used Observed Smoothed 95% Confidence Interval Days since randomization
22 Results: Outcomes, intention-to-treat A Sudden + Ventricular Tachyarrhythmia Death Control WCD
23 Results: Outcomes, intention-to-treat B Non-sudden Death Control WCD
24 Results: Outcomes, intention-to-treat C Death from Any Cause Log-rank P=0.04 Control WCD 35.5% RR reduction
25 Results: Cause-specific death Clinical event type WCD (N=1524) Control (N=778) P value* FATAL EVENTS, n (%) Sudden Death (1 outcome) 25 (1.6%) 19 (2.4%) 0.18 Non-sudden death 21 (1.4%) 17 (2.2%) 0.15 Congestive heart failure death 10 (0.7%) 5 (0.6%) 1.0 Recurrent MI death 1 (0.1%) 1 (0.1%) 1.0 Stroke death 0 (0.0%) 4 (0.5%) 0.01 Other cardiovascular death 5 (0.3%) 3 (0.4%) 1.0 Other death 5 (0.3%) 4 (0.5%) 0.72 Indeterminate death 2 (0.1%) 2 (0.3%) 0.83 Death, any cause 48 (3.1%) 38 (4.9%) 0.04 NON-FATAL EVENTS, n (%) Rehospitalization, cardiovascular 334 (22%) 174 (22%) 0.81 Rehospitalization, any cause 475 (31%) 253 (33%) 0.51
26 Results: WCD therapies & events Therapies Appropriate shocks (p=0.002) WCD Group (N=1524) Control Group (N=778) 1 appropriate shock 13 (0.9%) 0 (0%) 2 appropriate shocks 7 (0.5%) 1 (0.1%) Inappropriate shocks (p=0.05) 1 inappropriate shock 8 (0.5%) 0 (0%) 2 inappropriate shocks 2 (0.1%) 0 (0%) Aborted shocks (p<0.001) 1 aborted shock 43 (2.8%) 0 (0%) 2 aborted shocks 12 (0.8%) 0 (0%) >5 aborted shocks 15 (1.0%) 0 (0%)
27 Results: Pre-specified symptoms Characteristics WCD Control P value Fatigue 36.0% 38.8% 0.21 Back pain 20.0% 19.4% 0.73 Trouble sleeping 39.0% 37.3% 0.47 Dizziness 24.3% 23.5% 0.66 Fainting 4.2% 5.1% 0.34 Nausea 9.4% 12.0% 0.06 Headache 18.3% 19.1% 0.66 Palpitations 23.1% 25.7% 0.18 Chest pain 18.7% 21.4% 0.14 Shortness of breath 38.7% 45.4% Rash in any location 15.2% 7.1% <0.001 Rash on torso 12.9% 3.8% <0.001 Itch in any location 17.2% 6.4% <0.001 Itch on torso 14.5% 3.1% <0.001
28 Discussion: Sudden death outcome Possible misclassification of sudden deaths Reducing power for SD outcome but not total mortality 14 of 20 participants who received an appropriate shock survived to 90 days WCD may confer additional protection beyond SD Earlier care for bradycardia, NSVT or aborted shocks Lower stroke death in WCD group Reduced anxiety or increased medication compliance More shortness of breath in controls
29 Discussion: Limitations Participants and investigators not blinded Differences in shortness of breath between groups No differences in prescribing guideline-directed Rx Crossovers 20 participants in Control group received the WCD 19% in WCD group did not use the WCD Should bias results toward the null, but still found a difference in total mortality
30 Conclusions The WCD did not statistically significantly reduce sudden death mortality The WCD did reduce total mortality in the first 90 days post-mi in patients with LVEF 35% Relative risk reduction of 35.5% VEST represents the first randomized, controlled trial of the WCD Prescribing the WCD is reasonable to protect high-risk patients with a low LVEF post-mi until evaluation for an ICD at days
31 Thank you
Vest Prevention of Early Sudden Death Trial (VEST)
ACC Late Breaking Clinical Trials 2018 Vest Prevention of Early Sudden Death Trial (VEST) Jeffrey Olgin, MD, FACC Division of Cardiology, UCSF On behalf of the VEST Investigators Disclosures ClinicalTrials.gov
Risk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
LifeVest. Sven Reek, Aarau. Conflict of interest: none
LifeVest Sven Reek, Aarau Conflict of interest: none WCD (LifeVest, ZOLL, Pittsburg,PA) Technical aspects Wearable garment with 4 dry ECG electrodes (detection) 3 defibrillation pads External defibrillator
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
ICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
ICD Guidelines: who benefits from an ICD?
ICD Guidelines: who benefits from an ICD? Matthew Bennett Cardiac Electrophysiologist Vancouver Coastal Health, Device Lead Associate Professor, UBC Matthew.bennett@vch.ca Disclosures I have research collaborations
Wearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2017 Origination: 10/1988 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
Tachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
Wearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2018 Origination: 10/1988 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
The Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
Sudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
Preventing cardiac arrest in high risk patients without indication for ICD
Preventing cardiac arrest in high risk patients without indication for ICD Martin C. Burke, DO Chief Scientific Officer CorVita Science Foundation COI DISCLOSURES Funded by and NIH/SBIR grant to AJ Medical
Sudden Cardiac Death in Heart Failure: What do we need to know in 2018? Juan M. Aranda, Jr. MD FACC
Sudden Cardiac Death in Heart Failure: What do we need to know in 2018? Juan M. Aranda, Jr. MD FACC Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida Disclosures
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
News der kardialen Device - Therapie! Christian Binggeli! Rhythmologie Klinik St. Anna, Luzern! HerzGefässZentrum Zürich, KlinikImPark, Zürich!
News der kardialen Device - Therapie! Christian Binggeli! Rhythmologie Klinik St. Anna, Luzern! HerzGefässZentrum Zürich, KlinikImPark, Zürich! Complications after Implantation / Replacement / Upgrade
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Wearable Cardioverter Defibrillators Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Wearable Cardioverter Defibrillators Implantable Cardioverter
Zoll Medical--LifeVest:
Zoll Medical--LifeVest: Territory Manager: Sunny Brown Cell: (818) 916-6520 Objectives Why the LifeVest device exist Review indications for Wearable Cardioverter Defibrillator (WCD) use Give a brief description
Preventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
Role of Non-Implantable Defibrillators in the Management of Patients at High Risk for Sudden Cardiac Death
Role of Non-Implantable Defibrillators in the Management of Patients at High Risk for Sudden Cardiac Death 29 October 2011 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Associate
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
Sudden cardiac death (SCD) accounts for > deaths in
Sudden cardiac death (SCD) accounts for >300 000 deaths in the United States annually. 1 Although the majority of these deaths occur in low-risk populations 2 in which aggressive interventions are not
4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
Alex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
Do All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
Wearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2013 Origination: 10/1988 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
ICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation
Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation Objectives Current rationale behind use of MCS Patient Selection Earlier?
Wearable Cardioverter-Defibrillators
Medical Policy Manual Durable Medical Equipment, Policy No. 61 Wearable Cardioverter-Defibrillators Next Review: June 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER Medical Policies
Who does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
Synopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
Quality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
Implantable Cardioverter- Defibrillators (ICDs) for the Prevention of SCD: Appropriate Use in Disclosures
Implantable Cardioverter- Defibrillators (ICDs) for the Prevention of SCD: Appropriate Use in 2015 Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief,
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
SCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial
SCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial Gust H. Bardy Seattle Institute for Cardiac Research Seattle, Washington Disclosures Research grants, speaking fees Medtronic Research grants Wyeth
Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
Abbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1
2017 AHA/ACC/HRS Systematic Review for the Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Data Supplement Table of Contents Part 1. For Asymptomatic
National Medical Policy
National Medical Policy Subject: Policy Number: Cardiac Defibrillators - External, Automatic NMP269 Effective Date*: May 2006 Updated: May 2017 This National Medical Policy is subject to the terms in the
ARRHYTHMIAS AND DEVICE THERAPY
Topic List A BASICS 1 History of Cardiology 2 Clinical Skills 2.1 History Taking 2.2 Physical Examination 2.3 Electrocardiography 2.99 Clinical Skills - Other B IMAGING 3 Imaging 3.1 Echocardiography 3.2
Polypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
Wearable Devices for Heart Disease, Diabetes and Health
Wearable Devices for Heart Disease, Diabetes and Health Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health System
Controversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits
Continuous ECG telemonitoring with implantable devices: the expected clinical benefits C. W. Israel, M.D. Dept. of Cardiology Evangelical Hospital Bielefeld Germany Carsten.Israel@evkb.de Declaration of
Consensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
Supplementary Online Content
Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability 22nd Annual Heart Failure 2018: an Update on Therapy April 2018 Eric J. Velazquez, MD, FACP, FACC, FASE,
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
Medical Policy Manual. Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement
Medical Policy Manual Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement Date of Origin: February 5, 2003 Section: Durable Medical Equipment Last
Title: Automatic External Defibrillators Division: Medical Management Department: Utilization Management
Retired Date: Page 1 of 7 1. POLICY DESCRIPTION: Automatic External Defibrillators 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy,
The Counter HF Clinical Study for Heart Failure
The Counter HF Clinical Study for Heart Failure CAUTION: C-Pulse is an investigational device. It is limited by Federal (or United States) Law to investigational use only. 13-111-B Agenda Heart Failure
Guideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
Heart Failure Overview. Dr Chris K Y Wong
Heart Failure Overview Dr Chris K Y Wong Heart Failure: A Growing, Global Health Issue Heart Failure 23 Million Afflicted Global Impact Worldwide ~23 million peopleworldwide afflicted with CHF 1 Exceeds
Automatic External Defibrillators
Last Review Date: April 21, 2017 Number: MG.MM.DM.10dC3v4 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Hanna K. Al-Makhamreh, M.D., FACC Interventional Cardiologist
Hanna K. Al-Makhamreh, M.D., FACC Interventional Cardiologist Introduction. Basic Life Support (BLS). Advanced Cardiac Life Support (ACLS). Cardiovascular diseases (CVDs) are the number one cause of death
Arrhythmia in Acute Coronary Syndrome. E. Pruvot, MD, CHUV
Arrhythmia in Acute Coronary Syndrome E. Pruvot, MD, CHUV Background 10-15% of survivors of acute myocardial infarction (AMI) with LVEF die within the first 2 y after the event 1,2 80% of death are cardiac
Wearable Devices Emerging Strategies for Patient Management
Wearable Devices Emerging Strategies for Patient Management Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health System
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
Treatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
Re: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
Prophylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cardioverter-Defibrillators Page 1 of 32 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cardioverter-Defibrillators Professional Institutional Original Effective
GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
MEDICAL POLICY Cardioverter Defibrillators
POLICY........ PG-0224 EFFECTIVE......06/01/09 LAST REVIEW... 01/27/17 MEDICAL POLICY Cardioverter Defibrillators GUIDELINES This policy does not certify benefits or authorization of benefits, which is
Heart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction
2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction Ramzi Khalil MD FACC Assistant Professor Allegheny Gen.Hospital AHN Speakers
Randomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure (J-CHF) Study
82th AHA Meeting Nov 17, 2009 Orlando, USA Presenter Disclosure Information Randomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure
Chapter 8: Cardiovascular Disease in Patients with ESRD
Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)
Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.
Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical
Unknown ECGs for the Clinician
Unknown ECGs for the Clinician 2016 Bryan Heart Fall Cardiology Conference Andrew Merliss, MD, FACC, CDRS, FHRS Director of Cardiac Arrhythmia Service Bryan Heart Disclaimer Advisory Board for Medtronic
Patient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
Quality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
Early Experience of Transcatheter Mitral Valve Replacement Results from the Intrepid Global Pilot Study
Early Experience of Transcatheter Mitral Valve Replacement Results from the Paul Sorajja, MD for the Investigators Presenter Disclosure Information Within the past 12 months, I or my spouse/partner have
The Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
Clinical Investigations
Clinical Investigations Natural History and Implantable Cardioverter-Defibrillator Implantation After Revascularization for Stable Coronary Artery Disease With Depressed Ejection Fraction Address for correspondence:
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
ICD deactivation Patient Journey
ICD deactivation Patient Journey Julia decourcey Consultant Nurse Kings College Hospital 05.05.10 Internal Cardiac Defibrillator Used in pts at high risk of sudden cardiac death ie EF > 30% Previous survivor
InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions
InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions The Clinical Revisions provide details of changes to InterQual Clinical Criteria. They do not provide information on changes made to CareEnhance
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
Policy #: 168 Latest Review Date: October 2014
Name of Policy: Cardioverter Defibrillator: Implantable Policy #: 168 Latest Review Date: October 2014 Category: Surgery Policy Grade: A Background/Definitions: As a general rule, benefits are payable
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
Heart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
Acute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE
IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS Cardiology San Francisco General Hospital UCSF Disclosures: None LEADING CAUSES OF DEATH IN US Sudden cardiac
ESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
Congestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the